TY - JOUR
T1 - Direct evaluation of the microvascular actions of ANP in juxtamedullary nephrons
AU - Veldkamp, P. J.
AU - Carmines, P. K.
AU - Inscho, E. W.
AU - Navar, L. G.
PY - 1988
Y1 - 1988
N2 - The renal vascular actions of atrial natriuretic peptide (ANP) remain incompletely understood. The purpose of this study is to evaluate the effects of ANP on microvascular structures of the normal kidney. The in vitro blood-perfused juxtamedullary nephron technique was utilized to allow visualization of arcuate arteries and afferent and efferent arterioles. Donor rats were pretreated with captopril to eliminate possible interactions between angiotensin II and atriopeptin III (AP III). The effects of topical administration of 3 nM AP III were determined by videometric analysis of vessel inside diameters. Under control conditions, arcuate arterial diameter averaged 83 ± 14 μm (n = 7), afferent arteriolar diameter was 20 ± 4 μm (n = 7), and efferent arteriolar diameter was 16 ± 2 μm (n + 7). during superfusion with AP III, arcuate arteries and afferent arterioles diolated 73 ± 9 and 23 ± 5%, respectively. Both returned to their control values when AP III was removed from the superfusate. Further experiments on arcuate arteries (n = 5) revealed that 0.3 nM AP III also vasodilated these vessels (26 ± 9%); however, no significant effect was elicited by 0.03 nM AP III. In contrast to the vasodilator influence of AP III on preglomerular vessels, efferent arteriolar diameter was not altered by AP III exposure. These observations reveal that AP III can induce selective preglomerular vasodilation involving arcuate arteries as well as afferent arterioles, while efferent arteriolar diameter is not perceptibly influenced.
AB - The renal vascular actions of atrial natriuretic peptide (ANP) remain incompletely understood. The purpose of this study is to evaluate the effects of ANP on microvascular structures of the normal kidney. The in vitro blood-perfused juxtamedullary nephron technique was utilized to allow visualization of arcuate arteries and afferent and efferent arterioles. Donor rats were pretreated with captopril to eliminate possible interactions between angiotensin II and atriopeptin III (AP III). The effects of topical administration of 3 nM AP III were determined by videometric analysis of vessel inside diameters. Under control conditions, arcuate arterial diameter averaged 83 ± 14 μm (n = 7), afferent arteriolar diameter was 20 ± 4 μm (n = 7), and efferent arteriolar diameter was 16 ± 2 μm (n + 7). during superfusion with AP III, arcuate arteries and afferent arterioles diolated 73 ± 9 and 23 ± 5%, respectively. Both returned to their control values when AP III was removed from the superfusate. Further experiments on arcuate arteries (n = 5) revealed that 0.3 nM AP III also vasodilated these vessels (26 ± 9%); however, no significant effect was elicited by 0.03 nM AP III. In contrast to the vasodilator influence of AP III on preglomerular vessels, efferent arteriolar diameter was not altered by AP III exposure. These observations reveal that AP III can induce selective preglomerular vasodilation involving arcuate arteries as well as afferent arterioles, while efferent arteriolar diameter is not perceptibly influenced.
UR - http://www.scopus.com/inward/record.url?scp=0023927502&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023927502&partnerID=8YFLogxK
U2 - 10.1152/ajprenal.1988.254.3.f440
DO - 10.1152/ajprenal.1988.254.3.f440
M3 - Article
C2 - 2964792
AN - SCOPUS:0023927502
SN - 0002-9513
VL - 254
SP - F440-F444
JO - American Journal of Physiology - Renal Fluid and Electrolyte Physiology
JF - American Journal of Physiology - Renal Fluid and Electrolyte Physiology
IS - 3 (23/3)
ER -